JRCT ID: jRCT2080222410
Registered date:03/03/2014
Basic Information
Recruitment status | completed |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 13/11/2017 |
Target sample size | 166 |
Countries of recruitment | Asia except Japan,Japan,North America,Europe |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : trametinib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : dabrafenib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : Generic name etc : INN of investigational material : panitumumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | efficacy safety |
Key inclusion & exclusion criteria
Age minimum | >= 18age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | Novartis Pharma K.K. |
---|---|
Secondary Sponsor | - |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT01750918,JapicCTI-142460 |